Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

NCT02939014 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin Disease
Lymphoma, Large-Cell, Anaplastic

Interventions

DRUG: Brentuximab Vedotin

Sponsor

Takeda